Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.6MCash on Hand
CF+ Cash Runway
Follow ESYN by emailGet an email when ESYN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ESYN, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 27, 2026 ·
Shareholder vote EnerSyn Global will hold its 2026 virtual annual meeting on December 10, 2026, where shareholders vote to elect seven directors and ratify HTL International, LLC as independent auditor for 2026. Record date is October 13, 2026. Form DEF 14A · SEC filing
Sep 18, 2026 ·
Listing HWH International Inc. will change its name to EnerSyn Global Inc. effective September 18, 2026 at 11:00 PM Eastern. Trading under the new name and the symbol ESYN begins September 22, 2026. The CUSIP is unchanged and no shareholder vote was required. Form 8-K · SEC filing
Sep 11, 2026 ·
Deal HWH International agreed to buy Hearty Nova Limited from majority stockholder Smart Dynamics for $1.00, adding a 51% stake in a Nigeria gas processing joint venture with an anticipated $1,173,000 investment. Form 8-K · SEC filing
Sep 1, 2026 ·
Leadership HWH International's Chairman and CEO Chan Heng Fai stepped down from both roles and remains a director. Liu Ming Hui became Chairman and Liu Ming Xing became CEO, both joining the board on August 10, 2026. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Financing Sold 20,000,000 common shares and warrants for 160,000,000 shares at $0.63 to Smart Dynamics Technology Limited for $10,000,000, closing August 10, 2026. Purchaser now owns about 67.3% of outstanding shares and is the largest holder, a change of control. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
ESYN holds $1.6M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 33,726,400 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ESYN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ESYN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.